The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...

Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors ...

EQT Life Sciences is pleased to announce that the LSP Dementia Fund has co-led a USD 39 million Series A financing in Aerska, a biotechnology company leveraging brain shuttle technology to develop RNA ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

A nose-to-brain drug delivery approach leverages neural pathways to achieve high brain exposure with low systemic levels, offering a non-invasive alternative to transporter-based BBB strategies for ...